FATORES DETERMINANTES AO DESENVOLVIMENTO DE LITÍASE VESICULAR E PANCREATITE EM PACIENTES EM USO DE TIRZEPATIDA
DOI:
https://doi.org/10.63330/aurumpub.036-016Palabras clave:
Tirzepatida, Litíase vesicular, Pancreatite, GLP-1, Colelitíase, Efeitos adversos metabólicosResumen
A tirzepatida, agonista duplo dos receptores GIP e GLP-1, tem demonstrado elevada eficácia no controle glicêmico e na redução ponderal. Entretanto, efeitos adversos relacionados ao trato biliar e pancreático vêm sendo observados, incluindo litíase vesicular, colecistite e pancreatite aguda. Este artigo analisa criticamente os fatores fisiopatológicos, clínicos e metabólicos associados a essas complicações, destacando riscos, mecanismos prováveis e variáveis predisponentes.
Descargas
Referencias
FRIAS, J. P. et al. Efficacy and safety of tirzepatide versus placebo as add-on therapy to insulin in patients with type 2 diabetes (SURPASS-5). The Lancet, London, v. 398, n. 10300, p. 595-604, 2021.
JASTREBOFF, A. M. et al. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, Boston, v. 387, n. 3, p. 205-216, 2022.
LUDVIK, B. et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in type 2 diabetes (SURPASS- 3). The Lancet, London, v. 398, n. 10300, p. 583-598, 2021.
SINGH, S. et al. Glucagon-like peptide 1–based therapies and risk of gallbladder and biliary diseases: systematic review and meta-analysis. JAMA Internal Medicine, Chicago, v. 177, n. 11, p. 1-10, 2017.
SMITS, M. M.; VAN RAAIJ, E. P.; TACK, C. J. The role of GLP-1 receptor agonists in gallbladder motility and bile composition. Diabetes, Obesity and Metabolism, Oxford, v. 18, n. 4, p. 339-348, 2016.
BONORA, B. M. et al. Glucagon-like peptide-1 receptor agonists and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, Amsterdam, v. 128, p. 136-144, 2017.
NAU, C. K. et al. Rapid weight loss and risk of gallstone formation: pathophysiology and clinical implications. World Journal of Gastroenterology, Beijing, v. 19, n. 42, p. 1-8, 2013.
PORTINCASA, P. et al. Gallstone disease: pathophysiology and clinical management. Journal of Gastroenterology and Hepatology, Oxford, v. 31, n. 1, p. 1- 10, 2016.
ELASHOFF, M. et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology, Philadelphia, v. 141, n. 1, p. 150- 156, 2011.
ROSENSTOCK, J. et al. Once-weekly tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2). The New England Journal of Medicine, Boston, v. 385, n. 6, p. 503-515, 2021.
Descargas
Publicado
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
